Open house drug discount agreements Nintedanib

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework

Structured notice only

Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nintedanib, ATC L01EX09

40/100

Opportunity Score

Needs reviewLow complexity

SuppliesFrameworkOpen

Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Framework procurement
Supplies contract
1 lot
Duration until Apr 2028
Non-exclusive discount agreements for Nintedanib (ATC L01EX09) with pharmaceutical companies in Bavaria.
Open-house model: any eligible pharmaceutical company can join without selection.

Show full summary

Open-house model for non-exclusive drug discount agreements for Nintedanib (ATC L01EX09) by AOK Bayern. Not subject to procurement law. Contracts are offered to all interested pharmaceutical companies that meet eligibility criteria. No selection or award criteria. Contracts run from May 2026 to April 2028, with possible early termination. No estimated value provided.

Risks

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Eligibility

Eligibility: only pharmaceutical companies; submit signed self-declaration of reliability.

Administrative

Submission: either signed paper copy (two originals) or electronically with qualified electronic signature via DTVP portal.
Documents: completed and signed contract, annex listing medicines, and self-declaration of reliability.

Requirements may be incomplete.

Buyer

Name

AOK Bayern - Die Gesundheitskasse

Location

München, DEU

[email protected]

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house drug discount agreements Nintedanib

Non-exclusive discount agreements for the active substance Nintedanib (ATC L01EX09) under §130a(8) SGB V. All eligible pharmaceutical companies can join. Identical, non-negotiable terms. Contracts run from 01.05.2026 to 30.04.2028. Early termination possible with one month notice. Automatic suspension if a competitive discount contract is concluded.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Apr 2026 - Apr 2028

Procurement Details

Publication date: 15 Mar 2026
Languages: German

Reference metadata

Legal basis: 32014L0024

Reference IDs

Tender ID: 181186-2026

Documents (2)

Procurement document 1 Submission portal 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3